Samuel Backenroth
Geen lopende functies
Vermogen: 14 400 $ op 30-04-2024
Profiel
Samuel I.
Backenroth is the founder of Orphion Therapeutics, Inc., DepYmed, Inc. He previously worked as the Chief Financial Officer at Vascular Biogenics Ltd.
and Notable Labs Ltd.
From 2010 to 2019, he held the position of CFO, Secretary & Principal Accounting Officer at Ohr Pharmaceutical, Inc. In 2019, he served as the Chief Financial Officer, Secretary & Treasurer at Neubase Therapeutics, Inc. and NeuBase Therapeutics, Inc. Mr. Backenroth obtained his undergraduate degree from Touro College.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
0.17% | 31-03-2023 | 15 000 ( 0.17% ) | 14 400 $ | 30-04-2024 |
Eerdere bekende functies van Samuel Backenroth
| Bedrijven | Functie | Einde |
|---|---|---|
| NEUBASE THERAPEUTICS, INC. | Financieel Directeur/CFO | 30-09-2021 |
Neubase Therapeutics, Inc. /Old/
 Neubase Therapeutics, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Neubase Therapeutics, Inc. develops peptide-nucleic acid antisense oligonucleotide platform. Its platform address repeat expansion disorders, with an initial focus on huntington’s disease and myotonic dystrophy, as well as other dominant genetic disorders. The company was founded by Dietrich A. Stephan and is headquartered in Pittsburgh, PA. | Financieel Directeur/CFO | 01-01-2021 |
Ohr Pharmaceutical, Inc.
 Ohr Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology Ohr Pharmaceutical, Inc. engages in the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its product portfolio includes squalamine and SKS sustained release technology. The company was founded by Irach B. Taraporewala in 2008 and is headquartered in New York, NY. | Financieel Directeur/CFO | 01-01-2019 |
| NOTABLE LABS, LTD. | Financieel Directeur/CFO | - |
Opleiding van Samuel Backenroth
| Touro College | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| NEUBASE THERAPEUTICS, INC. | Health Technology |
| Bedrijven in privébezit | 5 |
|---|---|
Ohr Pharmaceutical, Inc.
Ohr Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology Ohr Pharmaceutical, Inc. engages in the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its product portfolio includes squalamine and SKS sustained release technology. The company was founded by Irach B. Taraporewala in 2008 and is headquartered in New York, NY. | Health Technology |
DepYmed, Inc.
 DepYmed, Inc. BiotechnologyHealth Technology DepYmed , Inc. is a cancer and rare disease therapeutic development company. The company is headquartered in Farmingdale, NY. | Health Technology |
Neubase Therapeutics, Inc. /Old/
Neubase Therapeutics, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Neubase Therapeutics, Inc. develops peptide-nucleic acid antisense oligonucleotide platform. Its platform address repeat expansion disorders, with an initial focus on huntington’s disease and myotonic dystrophy, as well as other dominant genetic disorders. The company was founded by Dietrich A. Stephan and is headquartered in Pittsburgh, PA. | Health Technology |
Orphion Therapeutics, Inc.
 Orphion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Orphion Therapeutics, Inc. develops novel gene therapies for the treatment of genetic disorders. The private company is based in Great Neck, NY. The company was founded by Samuel I. Backenroth. The CEO is Jason Scott Slakter. | Health Technology |
Vascular Biogenics Ltd.
 Vascular Biogenics Ltd. BiotechnologyHealth Technology Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of next-generation, targeted medicines for difficult-to-treat medical conditions. Its product candidates are built off of its platform technologies: Vascular Targeting System (VTS), a gene-based technology targeting newly formed blood vessels and Monocyte Targeting Technology (MTT), an antibody-based technology able to specifically inhibit monocyte migration for immune-inflammatory applications. The company was founded by Dror Harats and Jacob George on January 27, 2000 and is headquartered in Modi'in, Israel. | Health Technology |
